12th Market Access, Pricing & Reimbursement Global Congress 2025 Europe

Comprehensive Strategies and Embracing Innovations to Overcome Barriers in Patient Access

Copthorne Tara Hotel London Kensington, London, United Kingdom
  • 00Days
  • 00Hours
  • 00Minutes
  • 00Seconds

Market Access, Pricing & Reimbursement

Dear Colleagues,

Market access is the process of ensuring that patients have access to effective medicines and
medical technologies if and when they need them. Market access is a critical part of pharmaceutical strategies, and it’s important to remove any obstacles that prevent patients from receiving treatments. It is a crucial phase in a product’s lifecycle that can determine its commercial success.

The pharmaceutical market is expected to grow in the years to come regardless of a recent slowdown in key markets across the globe. The increase is exacerbated by the growing and ageing population in key markets. Aside from this, increasing access to Pharmaceuticals to poor and middle-class families due to increases in disposable income also drives the industry’s growth. Pharma companies focusing on Rare and speciality medicines is another aspect leading the growth. Innovations attracting investments even from non-pharma companies are also sustaining the growth in the pharmaceutical industry.

The pharmaceutical industry is one of the major players in the healthcare sector. Payers want to provide access and fund innovative treatments to improve patient care but governments across Europe are struggling to balance the desire to provide timely access to innovative medicines with the need to contain healthcare spending due to the increasing pressure between the demands of the EU, national governments and regional authorities.

As healthcare budgets are continuously rising in Europe, governments implement a wide variety of policies to control them with the help of different public regulatory bodies that are involved in pharmaceutical coverage decisions across Europe. International collaboration among HTA and regulatory bodies can promote knowledge exchange, as do the actions payers take in an effort to reduce costs while maintaining quality care.

The upcoming 2025, Market Access, Pricing and Reimbursement Global Congress Europe will present a dynamic approach to key trends and insights on market access, health
technology assessment, real-world data, patient access, pricing and reimbursement on the current European landscape.

This year, we are putting together an agenda that addresses “Comprehensive Strategies and Embracing Innovations to Overcome Barriers in Patient Access”. We are gathering together high calibre expert speakers to participate and share their knowledge and expertise through Keynote Presentations and Panel discussions, addressing all aspects of the industry.

We look forward to welcoming you to the MAPR 2025 congress!

Sincerely yours,  

Picture of Jocelyn Raguindin
Jocelyn Raguindin

Jocelyn is Conference Director at Facilitate Live. She has over 15+ years experience in organizing pharma-industry conferences and has been at the helm of every PGE conference since 2013. Jocelyn is based in London, UK.

Why you should attend:

GAIN THE LATEST INSIGHTS ON:

You Will Meet:

WHO SHOULD ATTEND: 

Network with members of boards, VP’s, Directors, Heads/Chiefs and Senior Managers of leading biopharmaceutical and biotech companies, government, CRO and solution providers involved in:

speakers
0 +
days Congress
0
Presentation
0 +
Attendees
0 +

Key Industry Expert Speakers

Professor James LEVINE MD PhD

President

Fondation Ipsen

MARTA CONTENTE

Sr Director, Pipeline Head of Immunology

GHEVO, TEVA

ROBERT MITCHELL-THAIN

CEO

PBC Foundation

Adrian Griffin

VP, HTA Market Access Policy

Johnson & Johnson

RIAD DIRANI

VP, Global HEOR, Medical Operations & Excellence

Teva

Alison Lawrence

Associate Principal

Decisive Consulting Ltd

Zavy Gabriel

Head of International Market Access

AstraZeneca

DR REBECCA GHOSH

Real-World Evidence Specialist

MHRA

Nazanin Mehin

Head of Global Market Access and Pricing for Immunology

Sanofi

Matthias Heck

Senior Advisor Strategic Alliance Development

EUCOPE

MARC DE BENEDETTI, PH.D.

Global Biometrics & Data Sciences, MMA, RWE CoE, BMS

Bristol Myers Squibb

Simon Lande

CEO & Co-founder

HealthLumen

Catherine Akesson

Senior Consultant, Strategic Market Access

Cogentia

OMAR ALI

Visiting Lecturer, VBA & Former Advisor

NICE, University of Portsmouth

LINDSAY BIRRELL

Co- CEO, Realise Advocacy, Chair of trustees

Medics 4 Rare Diseases

JOSIE GODFREY

Co-Founder and CEO, Realise Advocacy, Director

JG Zebra Consulting

Fleur Chandler

Patient Access Specialist, Chair

Project Hercules

Maria Rizzo

Senior Vice President, Evidence Synthesis

GIPAM GmbH

MATIAS OLSEN

Senior Manager, Public Affairs & Policy

EUCOPE

STEFANO ROMANELLI

Senior Government Affairs

EUCOPE

Schedule

Content Rich Program Agenda!  Featuring Keynote Presentations, Stream Sessions, Panel, and Round Table Discussions.

Matthias Heck, Senior Advisor Strategic Alliance Development, EUCOPE

MARKET ACCESS TRENDS & STRATEGIES

  • Navigating complex requirements to achieve and maintain market access in the EU and globally
  • Addressing varying market access and payer models to accelerate patient access to treatment
  • Integrating evidence development with market access strategy
  • Creating a robust clinical evidence for HTA assessment
  • Tackling the challenges on drug affordability

Moderator:

Alison Lawrence, Associate Principal, Decisive Consulting Ltd

Panelist:

Simon Lande, CEO & Co-founder, HealthLumen

  • Impact of the new EU Regulation on HTA, and the new requirements that companies need to address to access Member State markets.
  • Recommendations on how to ensure efficient and effective implementation of the JCA at the national level
  • Identify metrics that will enable iterative learning among stakeholders.
  • Future considerations for involvement in JCA and national implementation at the Member State level.

Adrian Griffin, VP, HTA & Access Policy, J&J Innovative Medicine

Points of Discussion to follow shortly

Marta Contente, Senior Director, Pipeline Head of Immunology, GHEVO, Teva

  • As interventional technologies gallop forward, payers react by evolving their methodologies for assessing effectiveness and willingness to reimburse. As we plan clinical development, we must strategise to ensure the best investment for patients, businesses, and the healthcare market. Accurate accounting for market access opportunities and challenges is critical across the pre-launch and post- launch timeline. This presentation will focus on how the pharmaceutical multidisciplinary team must work together to ensure the healthcare system can treat patients in a timely and effective way.

Alison Lawrence, Associate Principal, Decisive Consulting Ltd

  • In all HTA assessments, but specifically as part of the European JCA, companies are asked to provide comparative evidence for all relevant PICOs.
  • Whereas it is common sense that RCTs and literature-based indirect comparisons can generate that evidence, it is less clear what RWE can do in this respect
  • The presentation focuses on how such comparative RWE can be generated, and what needs to be taken
    into account regarding data access and methodology.

Thomas Wilke, PhD, Scientific Lead, GIPAM GmbH

  • The MHRA data strategy
  • Introducing the Real-World Evidence Scientific Dialogue Programme
  • The MHRA Real-World Data Guidance series

  Dr Rebecca Ghosh, Real-World Evidence Specialist, MHRA

  • Review use of RWD to guide pipeline and portfolio strategy
  • Considerations when using RWD to inform internal decisions
  • The growing use of data tokenization and advanced analytical techniques based on artificial
    intelligence in RWE
  • The importance of data quality and methodological transparency in RWE.

Riad Dirani, VP of Global HEOR, Medical Operations and Excellence, Teva

  • How to use patient-level external controls in a comparative efficacy analysis
  • Explore the evaluation and selection of index dates for RW subjects
  • Discuss the impacts and potential biases of common index date selection methods
  • Tips for considering which indexing method to use in studies that use external controls

Marc De Benedetti, Global Biometrics & Data Sciences, Bristol Myers Squibb

  • Challenges and obstacles in bringing this highly complex therapies to market
  • Lessons learned and applications for new entrants
  • Strategies that can be taken to improve timely market access and access for patients
  • Innovative contracting for cell & gene therapies in the EU
  • Stakeholder collaboration on the road towards a solution

Matias Olsen, Senior Manager, Public Affairs and Policy, EUCOPE

  • Access to innovative medicines remains a key issue worldwide
  • Identifying the root cause of inequitable access
  • Limitations of the some of the initiatives to address this such as the EUnetHTA JCA and the changes in
    legislation in Europe
  • Developing solutions that are sustainable and scalable
  • How can pharmaceutical companies and health authorities work together to bridge the gap

Moderator:
Matthias Heck, Senior Advisor Strategic Alliance Development, EUCOPE

Panellist:

Nazanin Mehin, Head of Global Market Access and Pricing for Immunology, Sanofi
Zavy Gabriel, Head of International Market Access, AstraZeneca

Matthias Heck, Senior Advisor Strategic Alliance Development, EUCOPE

CHALLENGES AND OPPORTUNITIES

  • Geopolitical drivers and access issues with high cost medicines
  • Pharma alignment on value and issues with demonstrating value propositions
  • Value based agreements and innovative contracting – real life cases from around the globe
  • Access and reimbursement models for combo oncology, multiple indications and cell/gene therapies

Omar Ali, Visiting Lecturer, VBA & Former Advisor, NICE, University of Portsmouth

  • Caregiver perspectives for different types of care
  • Burden or QOL?
  • A QALY is a QALY is a QALY – or is it?

Fleur Chandler, Patient Access Specialist, Chair, Project Hercules

  • Present cases studies demonstrating how automated evidence synthesis tools support different phases of clinical development, from early evidence planning to reimbursement and post-market surveillance.
  • Highlight how automation enhances decision-making and mitigates risks in market access by streamlining evidence generation and reducing redundancies.
  • Examine the integration of human expertise with AI-driven solutions, showcasing how co-piloted automation enhances efficiency while maintaining strategic oversight.

Maria Rizzo, Senior Vice President, Evidence Synthesis, GIPAM GmbH

  • Objective: Activating the full stakeholder ecosystem to shift conversation from price to value to get access to innovative therapies
  • Why is the full stakeholder ecosystem important for gaining access in the future?
  • How to Identify the stakeholder ecosystem for access success
  • Step by step: Setting up a cross-functional program for access success

Catherine Akesson, Senior Consultant, Strategic Market Access, Congentia

  • Points of Discussion to follow shortly

Nazanin Mehin, Head of Global Market Access and Pricing for Immunology, Sanofi

  • Points of Discussion to follow shortly

James Levine, President, Ipsen Foundation

  • Traditional methods for determining rare genetic disease patient populations often underestimate the true figures due to reliance on reported patient numbers.
  • Genetic database analysis provides a robust method to address these data gaps and determine more accurate estimates.
  • HealthLumen applied these techniques to estimate the prevalence of late-onset Fabry disease. The findings suggest Fabry prevalence may be up to three times higher than current estimates, revealing a large undiagnosed and untreated population.
  • This study demonstrates the power of genetic data to uncover hidden disease burden and help guide healthcare planning, policy, and therapeutic development for rare diseases.

Simon Lande, CEO and Co-founder, HealthLumen

  • The importance of making MA the core of the company
  • Bridge between pre-launch strategy and post-launch
  • Increasing collaboration between EU countries
  • Frontiers in Health Care
  • What will the future bring?

Moderator:
Catherine Akesson, Senior Consultant, Strategic Market Access, Congentia

Panellists:

2025 sponsors & Exhibitors

Newsletter Sign Up

No Spam – You will only receive relevant information on Market Access, Pricing & Reimbursement, and event updates

Testimonials

what people say

Thank you for a good experience with the PARADIGM Global Events… very high level, very good Organization, we overpassed our expectatives, we will be pending for another congress related to pharmaceutical and biotech… we learned a lot, and i think that the content of agenda was state of the art, thank you again.
Salvador Berrios
ERP/ CRM / Product Configurator Manager
The consistently high quality of international faculty was most impressive. It was also obvious that they were carefully chosen not only for their particular expertise but also for their ability to communicate the subject matter to clinical and non-clinical participants alike. As market access consultant for pharma clients of various sizes, I now feel much better prepared to explain the nuances & dynamics involved in bringing their products to market. In addition, I am in a much better position to intelligently advice my clients & help them set realistic expectations
Thomas Martin
Associate Vice President, VCGA - Quintiles
I was impressed with the organization of this event. I attend many conferences per year and find the organizers on site to be detached and not focus on good service to the delegates. This team was even providing weather forecast warning to ensure everyone was aware and made appropriate plans. Well Done.
Adriana E. Manzi
PhD, Managing Director, Atheln, Inc

Register To Attend Now!

Take Advantage of the Super Early Bird Discount. Group Discounts Also Available. 

Previous events

Book Your Place Now! 

Location

Scroll to Top